Hospitalization and Combined Use of Opioids, Benzodiazepines, and Muscle Relaxants in the United States
- PMID: 32999498
- PMCID: PMC7502868
- DOI: 10.1177/0018578719894702
Hospitalization and Combined Use of Opioids, Benzodiazepines, and Muscle Relaxants in the United States
Abstract
Introduction: Concurrent opioid and benzodiazepine use ("double-threat") and double-threat and muscle relaxant use ("triple-threat") are postulated to increase morbidity versus opioids alone. Study objectives were to measure association between double- and triple-threat exposure and hospitalizations in a validated, nationally representative database of the United States. Methods: A retrospective cohort study was conducted using the 2013 and 2014 Medical Expenditure Panel Survey (MEPS) longitudinal dataset and affiliated Prescribed Medicines Files. Association between 2013 and 2014 double- and triple-threat exposures and outcome of hospitalizations compared to nonusers, opioid users, and all combinations were assessed via logistic regression. The cohort surveyed in MEPS has been weighted to be reflective of the actual US population in the years 2013 and 2014. Logistic regression applying the subject-level MEPS survey weights was performed to measure association via odds ratios (ORs) of medication exposures with the outcome of all-cause hospitalization. Study subjects were categorized into exposure groups as nonusers (nonuse of opioids, benzodiazepines, or muscle relaxants), opioid users, benzodiazepine users, muscle relaxant users, "double-threat" users, and "triple-threat" users. Analyses were conducted using RStudio® 1.1.5 (Boston, MA) with α level = 0.05 for all comparisons. Results: Opioids, benzodiazepines, and muscle relaxants were used in 11.9% (38.4 million), 4.2% (13.5 million), and 3.4% (10.9 million) lives of the United States in 2013, respectively. Double-threat prevalence rose from 1.6% to 1.9% from 2013 to 2014. Triple-threat prevalence remained unchanged at 0.53%. Compared to nonusers, triple-threat patients increased hospitalization probability with ORs of 8.52 (95% confidence interval [CI]: 8.50-8.55) in 2013, 5.06 (95% CI: 5.04-5.08) in 2014, and 4.61 (95% CI: 4.59-4.63) in the 2013-2014 longitudinal analysis. Compared to nonusers, double-threat patients increased hospitalization probability with ORs of 5.71 (95% CI: 5.69-5.72) in 2013, 11.47 (95% CI: 11.44-11.49) in 2014, and 5.59 (95% CI: 5.57-5.60) in the longitudinal analysis. Conclusion: Concurrent opioid and benzodiazepine use and opioid, benzodiazepine, and muscle relaxant use were associated with increased hospitalization likelihood. Amplified efforts in surveillance, prescribing, monitoring, and deprescribing for concurrent opioid, benzodiazepine, and muscle relaxant use are needed to reduce this public health concern.
Keywords: analgesics; drug/medical use evaluation; outcomes research; pain management.
© The Author(s) 2019.
Conflict of interest statement
Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Similar articles
-
Association of combination opioid, benzodiazepine, and muscle relaxant usage with emergency department visits in a nationwide cohort in the United States.Int J Clin Pharm. 2021 Apr;43(2):358-364. doi: 10.1007/s11096-020-01012-5. Epub 2020 Apr 7. Int J Clin Pharm. 2021. PMID: 32266557
-
The association of tobacco use with prescription of muscle relaxants, benzodiazepines, and opioid analgesics for non-cancer pain.Am J Addict. 2019 Feb;28(2):63-70. doi: 10.1111/ajad.12830. Epub 2019 Jan 9. Am J Addict. 2019. PMID: 30623502
-
Comparative Risk of Opioid Overdose With Concomitant Use of Prescription Opioids and Skeletal Muscle Relaxants.Neurology. 2022 Sep 27;99(13):e1432-e1442. doi: 10.1212/WNL.0000000000200904. Epub 2022 Jul 14. Neurology. 2022. PMID: 35835561
-
Application of a diazepam milligram equivalency algorithm to assess benzodiazepine dose intensity in Rhode Island in 2018.J Manag Care Spec Pharm. 2022 Jan;28(1):58-68. doi: 10.18553/jmcp.2022.28.1.58. J Manag Care Spec Pharm. 2022. PMID: 34949119 Free PMC article.
-
Deprescribing Strategies for Opioids and Benzodiazepines with Emphasis on Concurrent Use: A Scoping Review.J Clin Med. 2023 Feb 23;12(5):1788. doi: 10.3390/jcm12051788. J Clin Med. 2023. PMID: 36902574 Free PMC article.
Cited by
-
Frailty Risks of Prescription Analgesics and Sedatives across Frailty Models: the Health and Retirement Study.Drugs Aging. 2022 May;39(5):377-387. doi: 10.1007/s40266-022-00941-2. Epub 2022 May 20. Drugs Aging. 2022. PMID: 35590086
-
Opioid Drug-Drug-Drug Interactions and Unintentional Traumatic Injury: Screening to Detect Three-Way Drug Interaction Signals.Front Pharmacol. 2022 May 10;13:845485. doi: 10.3389/fphar.2022.845485. eCollection 2022. Front Pharmacol. 2022. PMID: 35620282 Free PMC article.
-
New and persistent controlled substance use among patients undergoing mastectomy and reconstructive surgery.Breast Cancer Res Treat. 2021 Sep;189(2):445-454. doi: 10.1007/s10549-021-06275-8. Epub 2021 Jun 4. Breast Cancer Res Treat. 2021. PMID: 34089118
-
Population-based screening to detect benzodiazepine drug-drug-drug interaction signals associated with unintentional traumatic injury.Sci Rep. 2022 Sep 16;12(1):15569. doi: 10.1038/s41598-022-19551-4. Sci Rep. 2022. PMID: 36114250 Free PMC article.
-
New and Persistent Sedative-Hypnotic Use After Adjuvant Chemotherapy for Breast Cancer.J Natl Cancer Inst. 2022 Dec 8;114(12):1698-1705. doi: 10.1093/jnci/djac170. J Natl Cancer Inst. 2022. PMID: 36130058 Free PMC article.
References
-
- CDC Injury Center. Understanding the epidemic. Drug overdose; https://www.cdc.gov/drugoverdose/epidemic/index.html. Published July 24, 2019. Accessed October 8, 2019.
-
- National Institute on Drug Abuse. Overdose death rates. https://www.drugabuse.gov/related-topics/trends-statistics/overdose-deat.... Published January 29, 2019. Accessed September 12, 2019.
-
- Centers for Disease Control and Prevention (CDC). U.S. drug overdose deaths continue to rise; increase fueled by synthetic opioids. CDC Online Newsroom. https://www.cdc.gov/media/releases/2018/p0329-drug-overdose-deaths.html. Published September 24, 2018. Accessed April 16, 2019.
-
- The White House. Council of economic advisers report: the underestimated cost of the opioid crisis. https://www.whitehouse.gov/briefings-statements/cea-report-underestimate.... Published November 20, 2017. Accessed April 17, 2019.